BR0314945A - Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono - Google Patents

Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono

Info

Publication number
BR0314945A
BR0314945A BR0314945-5A BR0314945A BR0314945A BR 0314945 A BR0314945 A BR 0314945A BR 0314945 A BR0314945 A BR 0314945A BR 0314945 A BR0314945 A BR 0314945A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
treatment
sleep disorders
sleep
rem sleep
Prior art date
Application number
BR0314945-5A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Christoph Van Amsterdam
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32010223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314945(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0314945A publication Critical patent/BR0314945A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

"USO DE ANTAGONISTAS DE RECEPTOR 5-HT~ 2~ PARA TRATAMENTO DE DISTúRBIOS DE SONO". A presente invenção refere-se ao uso de antagonistas de receptor 5-HT~ 2~ para a preparação de um medicamento para estender ambos, sono não-REM e sono REM.
BR0314945-5A 2002-10-04 2003-09-03 Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono BR0314945A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10246357A DE10246357A1 (de) 2002-10-04 2002-10-04 Verwendung von 5-HT2Rezeptorantagonisten
PCT/EP2003/009738 WO2004032932A1 (de) 2002-10-04 2003-09-03 Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen

Publications (1)

Publication Number Publication Date
BR0314945A true BR0314945A (pt) 2005-08-02

Family

ID=32010223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314945-5A BR0314945A (pt) 2002-10-04 2003-09-03 Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono

Country Status (18)

Country Link
US (1) US20060040951A1 (pt)
EP (1) EP1545531A1 (pt)
JP (1) JP2006503870A (pt)
KR (1) KR20050054996A (pt)
CN (1) CN1688309A (pt)
AR (1) AR041476A1 (pt)
AU (1) AU2003283237A1 (pt)
BR (1) BR0314945A (pt)
CA (1) CA2501082A1 (pt)
DE (1) DE10246357A1 (pt)
MX (1) MXPA05003437A (pt)
PE (1) PE20040569A1 (pt)
PL (1) PL374077A1 (pt)
RU (1) RU2005113712A (pt)
TW (1) TW200410691A (pt)
UA (1) UA79993C2 (pt)
WO (1) WO2004032932A1 (pt)
ZA (1) ZA200503520B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865939A (en) * 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
DE3119383A1 (de) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
DE60004479T2 (de) * 1999-02-03 2004-06-24 Forbes Medi-Tech Inc., Vancouver Verfahren zur herstellung von phytosterol- oder phytostanol-mikropartikeln
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US6391370B1 (en) * 1999-11-12 2002-05-21 Kraft Foods, Inc. Micromilling plant sterols and emulsifiers
US6576285B1 (en) * 2000-11-14 2003-06-10 Sunpure Ltd. Cholesterol lowering beverage
DE10102944A1 (de) * 2001-01-23 2002-07-25 Merck Patent Gmbh Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten

Also Published As

Publication number Publication date
ZA200503520B (en) 2006-02-22
PL374077A1 (en) 2005-09-19
JP2006503870A (ja) 2006-02-02
AU2003283237A1 (en) 2004-05-04
TW200410691A (en) 2004-07-01
DE10246357A1 (de) 2004-04-15
EP1545531A1 (de) 2005-06-29
US20060040951A1 (en) 2006-02-23
MXPA05003437A (es) 2005-07-05
WO2004032932A1 (de) 2004-04-22
CN1688309A (zh) 2005-10-26
RU2005113712A (ru) 2005-11-20
PE20040569A1 (es) 2004-08-30
AR041476A1 (es) 2005-05-18
KR20050054996A (ko) 2005-06-10
UA79993C2 (en) 2007-08-10
CA2501082A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0213358A (pt) Uso de flibanserina
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
UY26291A1 (es) Compuestos químicos xxii
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2004041272A3 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
EE9900595A (et) Spetsiifilise 5-HT 2A-retseptori antagonisti kasutamine une hingamishäirete raviks kasulike ravimite valmistamiseks
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
PL1697005T3 (pl) Kombinacja flupirtyny i tramadolu
BRPI0516749A (pt) composições e métodos para tratamento de disturbìos cognitivos
BR0314945A (pt) Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
BR0312026A (pt) Microcápsulas para a liberação retardada e controlada do perindopril
PL1781292T3 (pl) Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu
BR0015310A (pt) Uso de agonistas do receptor de dopamina d3
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia
HK1082188A (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
BR0115297A (pt) Usos de antagonistas seletivos do receptor de dopamina d2 e agonistas do receptor 5-ht1a combinados
UA94465C2 (ru) Комбинированные препараты с содержанием бифепрунокса и l-dopa
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.